Skip to main content

Table 1 Patient characteristics among the 96 ovarian cancer samples

From: Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer

  N (%) Median PFS in months (95 % CI) P-value
All 96 18.0 (15.3–21.4)  
Age <60 41 (43 %) 22.2 (13.7–35.4) 0.25
  > =60 55 (57 %) 17.1 (13.6–20.5)  
Stage III 67 (70 %) 20.0 (16.3–30.0) 0.03
 IV 29 (30 %) 14.4 (12.7–19.2)  
Residual disease 0 cm 43 (45 %) 28.9 (21.1–55.5) <0.01
  > 0 cm 53 (55 %) 14.1 (12.1–16.5)